Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $42.00

Dyne Therapeutics (NASDAQ:DYN) had its price target hoisted by Chardan Capital from $31.00 to $42.00 in a research note published on Tuesday morning, MarketBeat reports. They currently have a buy rating on the stock.

Other analysts have also issued reports about the stock. Jefferies Financial Group lifted their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a buy rating in a research report on Monday. HC Wainwright lifted their target price on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a buy rating in a research report on Monday. Piper Sandler lifted their target price on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. Oppenheimer reiterated an outperform rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Monday, May 6th. Finally, Stifel Nicolaus boosted their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a buy rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $40.78.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $31.25 on Tuesday. The firm’s 50-day moving average is $27.05 and its 200-day moving average is $20.50. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $35.98. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -7.87 and a beta of 1.00.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.81). Equities analysts predict that Dyne Therapeutics will post -3.1 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 248,219 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $23.72, for a total transaction of $5,887,754.68. Following the transaction, the director now directly owns 903,527 shares in the company, valued at $21,431,660.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Wildon Farwell sold 1,585 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the sale, the insider now directly owns 151,590 shares of the company’s stock, valued at $3,895,863. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jason P. Rhodes sold 248,219 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $23.72, for a total transaction of $5,887,754.68. Following the sale, the director now directly owns 903,527 shares of the company’s stock, valued at $21,431,660.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 934,841 shares of company stock worth $23,103,069. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Federated Hermes Inc. bought a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $4,988,000. Assenagon Asset Management S.A. raised its holdings in shares of Dyne Therapeutics by 24.5% during the third quarter. Assenagon Asset Management S.A. now owns 721,474 shares of the company’s stock worth $6,464,000 after acquiring an additional 142,083 shares during the period. Acuta Capital Partners LLC raised its holdings in shares of Dyne Therapeutics by 100.7% during the third quarter. Acuta Capital Partners LLC now owns 146,500 shares of the company’s stock worth $1,313,000 after acquiring an additional 73,500 shares during the period. TD Asset Management Inc acquired a new stake in shares of Dyne Therapeutics during the third quarter worth $206,000. Finally, Profund Advisors LLC raised its holdings in shares of Dyne Therapeutics by 9.8% during the third quarter. Profund Advisors LLC now owns 23,793 shares of the company’s stock worth $213,000 after acquiring an additional 2,131 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.